Bioventix PLC $ 14.71 0 (0%)
Volume:
0
Avg Vol (1m):
0
Market Cap $:
276.79 Mil
Enterprise Value $:
265.88 Mil
P/E (TTM):
31.18
P/B:
17.92
Financial Strength | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | No Debt | ||
| Equity-to-Asset | 0.94 | ||
| Interest Coverage | No Debt | ||
| Piotroski F-Score | 9 | ||
| Altman Z-Score | 177.51 | ||
| Beneish M-Score | -2.55 | ||
| WACC vs ROIC | |||
Profitability Rank | 9/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 77.39 | ||
| Net Margin % | 69.84 | ||
| ROE % | 65.14 | ||
| ROA % | 60.4 | ||
| ROC (Joel Greenblatt) % | 206.48 | ||
| 3-Year Revenue Growth Rate | 12.3 | ||
| 3-Year EBITDA Growth Rate | 11.6 | ||
| 3-Year EPS without NRI Growth Rate | 13.4 |
BVNXF
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 31.18 | ||
| PE Ratio without NRI | 31.18 | ||
| Price-to-Owner-Earnings | 25.83 | ||
| PB Ratio | 17.92 | ||
| PS Ratio | 21.77 | ||
| Price-to-Free-Cash-Flow | 30.58 | ||
| Price-to-Operating-Cash-Flow | 29.23 | ||
| EV-to-EBIT | 27.05 | ||
| EV-to-EBITDA | 26.61 | ||
| EV-to-Revenue | 20.94 | ||
| PEG Ratio | 1.58 | ||
| Shiller PE Ratio | 60.41 | ||
| Current Ratio | 16.42 | ||
| Quick Ratio | 16.09 | ||
| Days Inventory | 104.05 | ||
| Days Sales Outstanding | 22.62 | ||
| Days Payable | 42.63 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Dividend Growth Rate | 19.8 | ||
| 3-Year Average Share Buyback Ratio | -0.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 17.94 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.82 | ||
| Price-to-Peter-Lynch-Fair-Value | 1.58 | ||
| Price-to-Graham-Number | 4.99 | ||
| Earnings Yield (Greenblatt) % | 3.7 | ||
| Forward Rate of Return (Yacktman) % | 21.79 |